Shaping the Future of Nonclinical Safety for Gene Therapy in 2025

Registration is required for this free webinar

Hosted by: SOT Biotechnology Specialty Section

Nonclinical safety for gene therapy has evolved over the last 10 years with the number of projects progressing into clinical trials and recent approvals. The data generated and experienced gained with these modalities has enabled us to modify our nonclinical strategies to streamline development and ensure an adequate nonclinical risk assessment. This presentation will highlight how preclinical and clinical experience within gene therapy can be applied to the development of these innovative medicines.

Speaker:

Nicholas Buss, PhD, Associate Vice President, Eli Lilly